Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Elimination of Minimal Residual Disease After Transplant
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 31
- Registration Number
- NCT05690984
- Locations
- 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 169
- Registration Number
- NCT05690191
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05683171
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 100
- Registration Number
- NCT05665140
- Locations
- 🇩🇪
Heloisklinikum Berlin Buch GmbH, Berlin, Germany
🇩🇪Klinikum Bielefeld - Onkologie, Hämatologie, Paliativmedizin, Bielefeld, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 180
- Registration Number
- NCT05660967
- Locations
- 🇺🇸
UW Cancer Center at ProHealth Care, Waukesha, Wisconsin, United States
🇦🇹Kepler Universitätsklinikum, Linz, Austria
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT05626322
- Locations
- 🇺🇸
LSU Health Baton Rouge North Clinic, Baton Rouge, Louisiana, United States
🇺🇸Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
🇺🇸Thompson Cancer Survival Center, Knoxville, Tennessee, United States
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Conditions
- Interventions
- First Posted Date
- 2022-11-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1116
- Registration Number
- NCT05623020
- Locations
- 🇮🇹
ASL PESCARA-Presidio Ospedaliero Pescara, Pescara, Italy
🇮🇹AOU Policlinico Umberto I, Roma, Italy
🇦🇺Pindara Private Hospital, Benowa, Queensland, Australia
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05615636
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunomodulators on HIV-1 Reservoir
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 48
- Registration Number
- NCT05598580
- Locations
- 🇨🇳
the first affiliated hospital of Zhejiang university school of medicine, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.